Overview

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of combining the disulfiram (DSF) and copper gluconate (Cu) to liposomal doxorubicin to treat patients with sarcomas that recurred or did not respond to initial treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Case Comprehensive Cancer Center
Treatments:
Copper
Disulfiram
Doxorubicin
Liposomal doxorubicin